[Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas].
Morbidity and mortality are increased in diabetic patients with ischemic heart disease. Sulfonylureas are the therapeutic group most frequently used and contributing to this. Patients usually treated with sulfonylureas have increased cardiovascular mortality. This is probably attributed to the action of these drugs on the ATP-sensitive potassium channels via blocking the ischemic preconditioning. This article puts forward evidence on sulfonylureas cellular and molecular pharmacodynamics and the real clinical incidence in the ATP-sensitive potassium channels inhibition in the diabetic patient's ischemic heart.
Gonçalves
J V
JV
Ciclo de Estudos Especiais de Diabetologia na Clínica de Diabetes e Nutrição do Serviço de Medicina IV do Hospital de Santa Maria.
Caldeira
J
J
D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced; D017202:Myocardial Ischemia / Q000139:chemically induced* / Q000401:mortality; D012307:Risk Factors; D013453:Sulfonylurea Compounds / Q000009:adverse effects*
D013453:Sulfonylurea Compounds